Skip to content

SAFETY OF MYGLYINDEX SOUP IN TYPE 2 DIABETIC PATIENTS

A RANDOMIZED OPEN LABEL PARALLEL GROUP PROOF OF CONCEPT STUDY TO EVALUATE THE SAFETY OF MYGLYINDEX SOUP IN REDUCING THE BLOOD SUGAR LEVELS IN TYPE 2 DIABETIC PATIENTS

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052373
Enrollment
30
Registered
2023-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications

Interventions

None listed

Sponsors

BR Medical Research and Software Solutions (OPC) Private Limited.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Willing and able to provide written informed consent prior to performing study procedures. 2. Patients between the age of 18-80 years. 3. Males or females; females must be non-pregnant / non-lactating and practicing adequate birth control measures if not menopausal. 4. Type 2 DM patients on oral hypoglycemic agents 5. Patient should have not participated in any other clinical trial during the past 3 months.

Exclusion criteria

Exclusion criteria: 1. Patient who are unable to consume solid and liquid orals. 2. Patients who are having complications of Diabetes mellitus and suffering from other severe co morbid conditions. 3. Hypersensitivity to test product. 4. History of drug or alcohol abuse. 5. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment.

Design outcomes

Primary

MeasureTime frame
Fasting and Post prandial blood sugar levels (total venous blood sample of 5 ml is required).Timepoint: Day 1

Secondary

MeasureTime frame
Adverse events and serious adverse events during the study period Brief clinical examinationTimepoint: Day 1

Countries

India

Contacts

Public ContactDr Gayathri Sivakumar

ki3

saheerose@gmail.com9443627722

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026